Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals, the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan A. J. W.
  • Ferrari, Matteo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • McNamara, Iain R.
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Waiyan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia|||0000-0001-8138-0874
  • Ustianowski, Andrew P.
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Del-Toro-López, Maria Dolores
The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections, a post-hoc analysis of a multicentre prospective cohort in Spain

  • Gómez-Zorrilla, S.
  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Sendra, Elena|||0000-0002-4374-2173
  • Zamorano, L.
  • Grau, I.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, E.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • López Montesinos, I.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Cotarelo, M.|||0000-0002-7017-0369
  • Cantón, R.
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, P.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48-72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11-4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37-25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25-4.69), cephalosporins (2.14; 1.35-3.41), and imipenem or meropenem (2.08; 1.03-4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain, Findings from the Multicenter ITUBRAS-2 Cohort Study

  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Hernández García, Marta
  • Xanthopoulou, K.|||0000-0001-8591-8184
  • Gijón, Desiré
  • Siverio Pares, Ana Cristina
  • Berbel, Dàmaris|||0000-0002-3689-3360
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Rivera, Alba|||0000-0002-9709-6162
  • de Malet, A.
  • Xercavins, M.|||0000-0003-1463-6344
  • Ruiz De Gopegui, E.
  • Canoura-Fernández, L.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Seral, C.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Cotarelo, M.|||0000-0002-7017-0369
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Higgins, P.G.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, A.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Ruiz-Garbajosa, P.
  • Montesinos, I.L.
  • Merino, I.
  • de Gopegui, E.R.
  • López-Causapé, C.
  • Grau, I.
  • Sabé, N.
  • Shaw, E.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Sendra, E.
  • Rubio, V.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Badía, C.
  • Calvo, E.
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Morte-Romea, E.
  • Paño-Pardo, J.R.
  • Carmona-Torre, F.
  • Quintano, F.T.
  • Sánchez Carrillo, Carlos
  • Cortarelo, M.
Background: The objective of this study was to assess the microbiological and clinical features of Klebsiella pneumoniae health care-associated bacteremia of urinary origin (HCA-BUO) in Spain, with a focus on third-generation cephalosporin-(3GCR-Kp) and carbapenem-resistant K pneumoniae (CR-Kp) isolates. Methods: A total of 96 (21.4%, 96/449) K pneumoniae blood isolates were prospectively collected from patients with HCA-BUO (n = 443) from 12 tertiary care hospitals in Spain (2017-2019). Antimicrobial susceptibility was determined (standard broth microdilution), and extended-spectrum β-lactamase, AmpC, and carbapenemase production was screened. A subset of 55 K pneumoniae isolates was analyzed by whole genome sequencing (Illumina) to determine population structure, resistome, and virulome. Additionally, 13 of these isolates were subjected to long-read sequencing (Nanopore) for plasmid characterization. Patients' baseline and clinical characteristics were reviewed. Results: 3GCR-Kp prevalence was 43.8% (42/96), mostly associated with extended-spectrum β-lactamase production (34/96, 35.4%; mainly CTX-M-15, 32/34, 94.1%) and the dissemination of sequence type (ST)-307 (15/34, 44.1%) and other globally spread multidrug-resistant high-risk clones. CR-Kp prevalence was 9.4% (9/96); all isolates belonged to different STs and were mostly associated with carbapenemase production (6/9, 66.7%; mainly OXA-48-like, n = 3). Additionally, 3GCR-Kp and CR-Kp isolates showed higher content of other antibiotic resistance genes. Altogether, these episodes were associated with prior antibiotic use and receipt of inadequate empirical treatment. Conclusions: There is a high prevalence of 3GCR and CR-Kp causing HCA-BUO in Spain, mainly driven by the dissemination of ST307/CTX-M-15 and other globally spread multidrug-resistant high-risk clones, challenging the selection of empirical and targeted treatments for these infections.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

  • Rombauts, Alexander
  • Infante, Carmen
  • Álamo Martínez de Lagos, Mikel del
  • Alba, Jorge
  • Valiente, Adoración
  • Donado-Mazarrón, Carla
  • Carretero-Ledesma, Marta
  • Rodríguez-Álvarez, Regino José
  • Omatos, Sonia
  • Palacios-Baena, Zaira Raquel
  • Abelenda, Gabriela
  • Silva-Sánchez, María del Mar
  • Goikoetxea-Aguirre, Josune
  • Oteo, José Antonio
  • Rodríguez-Baño, Jesús
  • Cordero, Elisa
  • Gudiol, Carlota
  • Sánchez-Céspedes, Javier
  • Carratalà, Jordi
As the COVID-19 pandemic has progressed, long-COVID has emerged as a major problem that poses a significant challenge for attending physicians and health care policy makers. Therefore, we read with much interest the recently published unicentre study in the Journal of Infection by Righi et al.,1 carried out on 465 adult COVID-19 patients (235 [50.5%] hospital-admitted) followed-up during nine months, concluding that those with advanced age, intensive care unit (ICU) admission, and multiple symptoms at onset were more likely to have long-term COVID-19 symptoms, with negative impact on physical and mental wellbeing. Other studies have found that female gender, age, longer hospital stay, pre-existing hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, smoking, obesity, and chronic alcoholism increase the likelihood of long-COVID.2,3 It is known that SARS-CoV-2 RNAemia is a predictor of COVID-19 severity and in-hospital complications.4,5 However, to the best of our knowledge, only two studies have assessed, up to one or three months after the acute COVID-19 onset, whether SARS-CoV-2 RNAemia may have an impact on long-COVID,6,7 both finding that RNAemia at presentation might predict the persistence of symptoms. However, these studies did not provide information regarding long-COVID symptoms nor the association with SARS-CoV-2 RNAemia beyond three months, and could not differentiate between “true” long-COVID and the convalescence phase of the SARS-CoV-2 infection., A.R. has received a predoctoral research grant from the Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities, (PFIS grant FI18/00183). G.A.A. reports a predoctoral research grant from the 201808-10 project, funded by La Marató de TV3. This study was supported by the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0005, RD16/0016/0009, RD16/0016/0013)-co-financed by the European Development Regional Fund, A way to achieve Europe, Operative program Intelligent Growth 2014-2020, and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) [CB21/13/00009; CB21/13/00006], Madrid, Spain. J.S.C. and E.C. received grants from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Proyectos de Investigación sobre el SARS-CoV-2 y la enfermedad COVID-19 (COV20/00580; COV20/00370). J.S.C. is a researcher belonging to the program “Nicolás Monardes” (C-0059–2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain. Samples and data from patients included in this study from the Hospital Universitario Cruces (Bizkaia, Spain) were provided by the Basque Biobank (www.biobancovasco.org) and were processed following standard operation procedures with appropriate approval of the Ethical and Scientific Committees., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad
  • Mur, Isabel
  • Tedeschi, Sara
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa
  • Murillo, Óscar
  • Soldevila-Boixader, Laura
  • Scarborough, Mathew
  • Scarborough, Claire
  • Kluytmans, Jan
  • Ferrari, Matteo Carlo
  • Pletz, Mathias W.
  • Mcnamara, Iain
  • Escudero-Sánchez, Rosa
  • Arvieux, Cédric
  • Batailler, Cecile
  • Dauchy, Frédéric-Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús
  • Toro, María Dolores del
© 2023 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background] The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres., [Methods] This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables., [Results] The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI., [Conclusions] This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI., This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E., L.S, O.M., R.E.-S., J.L.-T., J.P., J.R.-B. and M.D.del T. are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014–2020. M.W.P. was partly supported by the German Research Foundation (GRK 2723, project number 444711651)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

  • Sojo-Dorado, Jesús
  • López-Hernández, Inmaculada
  • Gutiérrez-Gutiérrez, Belén
  • Rosa-Riestra, Sandra de la
  • Docobo-Pérez, Fernando
  • Hernánez-Torres, Alicia
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Purpose] A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli., [Methods] Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed., [Results] Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition., [Conclusions] DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems used. Overall, fosfomycin was favoured when oral step-down treatment and use of antibiotics with lower ecological impact were included., The study was funded by grants RD16/0016/0001, 0002, 0003, 0005, 0007, 0008, 0009, 0011, 0012, and 0015 from Plan Nacional de Investigación, Desarrollo e Innovación (I + D + i) 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI); PT13/0002/0010 and PT17/0017/0012 from the Spanish Clinical Research and Clinical Trials Platform (SCReN); and PI 13/01282 co-financed by the European Development Regional Fund “A Way to Achieve Europe” and Operative Program Intelligence Growth 2014 to 2020. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla, Belén
  • Benito, Natividad
  • Boix-Palop, Lucía
  • Fariñas, Maria Carmen
  • Peñaranda, María
  • Gamallo, Maria Rocío
  • Martinez, Jose Antonio
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis
  • Durán-Jordá, Xavier
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael
  • Oliver, Antonio
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo
  • Siverio, Ana
  • Gijón, Desiré
  • Merino, Irene
  • López-Causapé, Carla
  • Sabé, Nuria
  • Shaw, Evelyn
  • Berbel, Dámaris
  • Tubau Quintano, Fe
  • Sánchez Carrillo, Carlos
  • Cercenado, Emilia
  • Sendra, Elena
  • Rubio, Verónica
  • Rivera, Alba
  • Calvo, Esther
  • Badía, Cristina
  • Xercavins, Mariona
  • de Malet, Ana
  • Canoura-Fernández, Luis
  • Salvo, Soledad
  • Paño-Pardo, Jose Ramón
  • Carmona-Torre, Francisco
Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77–6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27–6.44) and Charlson index (aOR 1.11; 95% CI 1.01–1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40–0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. © 2021, The Author(s).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multi drug resistance in healthcare-associated bacteremic urinary tract infections: a post-hoc analysis of a multi center prospective cohort in Spain

  • Gómez Zorrilla, S.
  • Becerra Aparicio, F.
  • Sendra, E.
  • Zamorano, L.
  • Grau, I.
  • Pintado, V.
  • Padilla, B.
  • Benito, N.
  • Boix Palop, L
  • Fariñas, M.C.
  • Peñaranda, M.
  • Gamallo, M.R.
  • Martínez, J.A.
  • Morte Romea, E.
  • Del Pozo, J.L.
  • López Montesinos, I.
  • Durán Jordá, X.
  • Ponz, R.
  • Cotarelo, M.
  • Cantón, R.
  • Oliver, A.
  • Ruiz Garbajosa, P.
  • Horcajada, J.P.
Background: The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48–72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11–4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37–25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25–4.69), cephalosporins (2.14; 1.35–3.41), and imipenem or meropenem (2.08; 1.03–4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

  • Gómez-Junyent, Joan
  • Lora-Tamayo, Jaime
  • Baraia-Etxaburu, Josu
  • Sánchez-Somolinos, Mar
  • Iribarren, Jose Antonio
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Staphylococcus aureus; Implant removal; Prosthetic joint infection, Staphylococcus aureus; Extracción de implantes; Infección de la articulación protésica, Staphylococcus aureus; Eliminació d’implants; Infecció de l'articulació protèsica, Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting., This study was supported by Plan Nacional I+D+I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), co-financed by the European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2004–2020. J. G-J was supported by a grant from the Spanish Ministry of Education (FPU 14/03124).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance, Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, Mª Carmen
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, Maria Rocío
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77-6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27-6.44) and Charlson index (aOR 1.11; 95% CI 1.01-1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40-0.93) were less likely to present clinical cure. The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. The online version contains supplementary material available at 10.1007/s40121-021-00537-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus, Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

  • Gómez-Junyent, Joan|||0000-0003-1752-1382
  • Lora-Tamayo, Jaime
  • Baraia-Etxaburu, Josu
  • Sánchez-Somolinos, Mar
  • Iribarren, José Antonio
  • Rodriguez-Pardo, Dolors|||0000-0001-6781-5405
  • Praena-Segovia, Julia|||0000-0001-8138-0874
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Bahamonde, Alberto
  • Riera, Melchor
  • Rico Nieto, Alicia|||0000-0002-4364-2973
  • del Toro López, María Dolores|||0000-0002-4935-8754
  • Morata, Laura|||0000-0001-5795-0814
  • Cobo, Javier
  • Falgueras, Luis
  • Benito, Natividad|||0000-0001-6410-013X
  • Muñez, Elena|||0000-0002-5256-097X
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Ariza, Javier|||0000-0003-0376-6960
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003-2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis, A Multicenter Matched Cohort Study

  • Escrihuela-Vidal, Francesc|||0000-0003-3652-3121
  • López Cortés, Luis Eduardo|||0000-0002-9347-527X
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Alarcón González, Arístides de|||0000-0002-4548-4462
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Sánchez Porto, Antonio|||0000-0001-6906-7017
  • Fernández Hidalgo, Nuria|||0000-0002-2115-344X
  • Luque, Rafael
  • Montejo, Miguel
  • Miró, José M.|||0000-0001-8057-7755
  • Goenaga, Miguel Ángel
  • Munoz, Patricia|||0000-0001-5706-5583
  • Valerio, Maricela|||0000-0001-6394-2861
  • Ripa, Marco
  • Sousa-Regueiro, Dolores
  • Gurguí, Mercè|||0000-0002-0474-3528
  • Fariñas, Mª Carmen
  • Mateu, Lourdes|||0000-0001-7223-7611
  • García Vázquez, Elisa
  • Gálvez-Acebal, Juan
  • Carratalà, Jordi|||0000-0003-3209-2563
Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess formation and embolic events, there is limited evidence to support this assumption. We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci (VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis. Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When comparing SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, P = .116); valve disorder, including perforation (22.2% vs 18.1%, P = .584), pseudoaneurysm (16.7% vs 8.3%, P = .108), or prosthesis dehiscence (1.4% vs 6.3%, P = .170); paravalvular complications, including abscess (25% vs 18.8%, P = .264) and intracardiac fistula (5.6% vs 3.5%, P = .485); heart failure (34.7% vs 38.9%, P = .655); or embolic events (41.7% vs 32.6%, P = .248). Indications for surgery (70.8% vs 70.8%; P = 1) and mortality (13.9% vs 16.7%; P = .741) were similar between groups. SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG. In this multicenter matched cohort study, we found that Streptococcus anginosus group endocarditis follows a similar course to endocarditis caused by viridans or gallolyticus group streptococci, regarding valvular complications and prognostic variables such as indication for surgery and mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rates and Predictors of Treatment Failure in Staphylococcus aureus Prosthetic Joint Infections According to Different Management Strategies, A Multinational Cohort Study-The ARTHR-IS Study Group

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan|||0000-0003-2665-6844
  • Ferrari, Mateo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • Mcnamara, Iain
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • del Toro López, María Dolores|||0000-0002-4935-8754
Guidelines have improved the management of prosthetic joint infections (PJI). However, it is necessary to reassess the incidence and risk factors for treatment failure (TF) of Staphylococcus aureus PJI (SA-PJI) including functional loss, which has so far been neglected as an outcome. A retrospective cohort study of SA-PJI was performed in 19 European hospitals between 2014 and 2016. The outcome variable was TF, including related mortality, clinical failure and functional loss both after the initial surgical procedure and after all procedures at 18 months. Predictors of TF were identified by logistic regression. Landmark analysis was used to avoid immortal time bias with rifampicin when debridement, antibiotics and implant retention (DAIR) was performed. One hundred twenty cases of SA-PJI were included. TF rates after the first and all surgical procedures performed were 32.8% and 24.2%, respectively. After all procedures, functional loss was 6.0% for DAIR and 17.2% for prosthesis removal. Variables independently associated with TF for the first procedure were Charlson ≥ 2, haemoglobin < 10 g/dL, bacteraemia, polymicrobial infection and additional debridement(s). For DAIR, TF was also associated with a body mass index (BMI).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia, Study protocol for the SAFO trial

  • Grillo, Sara|||0000-0002-3596-8690
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Carratalà, Jordi|||0000-0003-3209-2563
  • San-Juan, Rafael|||0000-0003-3446-1991
  • Aguado, José María|||0000-0002-9520-8255
  • Morata, Laura|||0000-0001-5795-0814
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Gasch, Oriol|||0000-0001-8518-458X
  • Gomila, Aina|||0000-0001-6979-9269
  • Iftimie, Simona
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Calbo Sebastián, Esther|||0000-0001-7750-5347
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Oriol, Isabel|||0000-0001-5542-7878
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • López Cortés, Luis Eduardo|||0000-0002-9347-527X
  • Euba, Gorane|||0000-0002-7869-4693
  • Aguirregabiria, Malen
  • Garcia-Pais, Maria Jose
  • Gioia, Francesca
  • Paño, Jose Ramón
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Benítez Díaz, Rosa María|||0000-0001-6972-6094
  • Pérez-Rodríguez, Maria Teresa
  • Meije, Yolanda
  • Loeches-Yagüe, Maria Belén
  • Horna, Gertrudis
  • Berbel, Dàmaris|||0000-0002-3689-3360
  • Domínguez, Maria Ángeles
  • Padullés, Ariadna|||0000-0003-1541-6001
  • Cobollés, Sara
  • Hereu, Pilar|||0000-0002-9191-8962
  • Videla, Sebastián|||0000-0001-5049-1379
  • Tebé, Cristian|||0000-0003-2320-1385
  • Pallarès, Natàlia
  • Miro, Josep M.
  • Pujol, Miquel|||0000-0002-6475-6208
Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a frequent condition, with high mortality rates. There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy. In vitro and small-scale studies have found synergy between cloxacillin and fosfomycin against S. aureus. Our aim is to test the hypothesis that cloxacillin plus fosfomycin achieves higher treatment success than cloxacillin alone in patients with MSSA bacteraemia. We will perform a superiority, randomised, open-label, phase IV-III, two-armed parallel group (1:1) clinical trial at 20 Spanish tertiary hospitals. Adults (≥18 years) with isolation of MSSA from at least one blood culture ≤72 hours before inclusion with evidence of infection, will be randomly allocated to receive either cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous or cloxacillin 2 g/4-hour intravenous alone for 7 days. After the first week, sequential treatment and total duration of antibiotic therapy will be determined according to clinical criteria by the attending physician. Primary endpoints: (1) Treatment success at day 7, a composite endpoint comprising all the following criteria: patient alive, stable or with improved quick-Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA at day 7. (2) Treatment success at test of cure (TOC) visit: patient alive and no isolation of MSSA in blood culture or at another sterile site from day 8 until TOC (12 weeks after randomisation). We assume a rate of treatment success of 74% in the cloxacillin group. Accepting alpha risk of 0.05 and beta risk of 0.2 in a two-sided test, 183 subjects will be required in each of the control and experimental groups to obtain statistically significant difference of 12% (considered clinically significant). Ethical approval has been obtained from the Ethics Committee of Bellvitge University Hospital (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency (AEMPS, AC069/18), and is valid for all participating centres under existing Spanish legislation. The results will be presented at international meetings and will be made available to patients and funders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis, A Randomized Clinical Trial

  • Pujol, Miquel|||0000-0002-6475-6208
  • Miró, José M.|||0000-0001-8057-7755
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Aguado, José María|||0000-0002-9520-8255
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Calbo Sebastián, Esther|||0000-0001-7750-5347
  • Montejo, Miguel
  • Rodriguez-Álvarez, Regino José
  • Garcia-Pais, Mª José
  • Pintado, Vicente
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Morata, Laura|||0000-0001-5795-0814
  • Montero, Milagros
  • Andrés Granyó, Marta|||0000-0003-3214-1636
  • Pasquau, Juan
  • Arenas, Maria Del Mar
  • Padilla Ortega, Belén
  • Murillas, Javier|||0000-0003-2169-7110
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • López Cortés, Luis Eduardo|||0000-0002-9347-527X
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Gasch, Oriol|||0000-0001-8518-458X
  • Videla, Sebastián|||0000-0001-5049-1379
  • Hereu, Pilar|||0000-0002-9191-8962
  • Tebé, Cristian|||0000-0003-2320-1385
  • Pallares Fontanet, Natalia|||0000-0002-1462-379X
  • Sanllorente, Mireia
  • Domínguez, María-Ángeles
  • Càmara, Jordi|||0000-0002-0817-0931
  • Ferrer, Anna
  • Padullés, Ariadna|||0000-0003-1541-6001
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Carratalà, Jordi|||0000-0003-3209-2563
We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval,. 93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems, Recomendaciones del Comité Español del Antibiograma (COESANT) para la selección de antimicrobianos y sus concentraciones en el estudio in vitro de la sensibilidad con métodos automáticos

  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Alós, Juan Ignacio
  • Benito, Natividad|||0000-0001-6410-013X
  • Bou, German|||0000-0001-8837-0062
  • Campos, José
  • Calvo, Jorge
  • Canut-Blasco, Andrés
  • Castillo, Javier
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Domínguez, Maria Ángeles
  • Fernández-Cuenca, Felipe
  • Guinea, Jesús
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Liñares, Josefina
  • López-Cerero, Lorena
  • López-Navas, Antonio
  • Marco, Francesc|||0000-0002-1863-6379
  • Mirelis, Beatriz
  • Moreno-Romo, Miguel Ángel
  • Morosini, María Isabel
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Pérez Trallero, Emilio
  • Pérez-Vázquez, María
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Torres, Carmen
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Martínez-Martínez, Luis
Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs., Los sistemas automáticos utilizados en el estudio de la sensibilidad a los antimicrobianos están introducidos en la mayoría de los laboratorios de Microbiología Clínica en España, utilizando principalmente los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST). En 2007, un grupo de expertos publicó unas recomendaciones para incluir antimicrobianos y seleccionar concentraciones en estos sistemas. Bajo el auspicio del Comité Español del Antibiograma (COESANT) y del Grupo de Estudio de los Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y alineado con el Plan Nacional frente a la Resistencia a los Antibióticos (PRAN), un grupo de expertos ha actualizado dicho documento. Las principales modificaciones realizadas sobre la versión anterior comprenden la inclusión de nuevos agentes antimicrobianos, la adaptación de los rangos de concentraciones para cubrir los puntos de corte clínicos y los puntos de corte epidemiológicos (ECOFF) definidos por el EUCAST, y para la inferencia de nuevos mecanismos de resistencia. Esta propuesta debería ser considerada por los diferentes fabricantes y los usuarios cuando se diseñen nuevos paneles o tarjetas. Además, se incluyen recomendaciones para realizar informes selectivos. Con este enfoque, la implementación de los puntos de corte del EUCAST será más fácil, aumentando la calidad de los datos del antibiograma y su interpretación microbiológica. También será de utilidad para los estudios de vigilancia epidemiológica, así como para el uso clínico de los antimicrobianos, de acuerdo con los programas de optimización de uso de antimicrobianos (PROA).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections, A Randomized Clinical Trial

  • Sojo-Dorado, Jesús
  • López-Hernández, I.
  • Rosso-Fernandez, C.
  • Palacios-Baena, Z.R.
  • Hernández-Torres, A.
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Bereciartua, Elena|||0000-0002-8603-779X
  • García-Vázquez, E.
  • Pintado, Vicente
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Natera-Kindelán, C.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Borrell, Nuria
  • Giner-Oncina, L.
  • Amador-Prous, C.
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Molina, J.
  • Martínez-Alvarez, R.M.
  • Dueñas, C.J.
  • Calvo-Montes, J.
  • Silva, J.T.
  • Cárdenes, M.A.
  • Lecuona, M.
  • Pomar, Virginia|||0000-0002-8473-5834
  • Valiente De Santis, L.
  • Yagüe-Guirao, G.
  • Lobo-Acosta, M.A.
  • Merino-Bohórquez, V.
  • Pascual, A.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Mirelis, Beatriz
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Viñado, Belén|||0000-0001-6212-5886
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Pujol, Miquel|||0000-0002-6475-6208
The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. Design, Setting, and Participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days. Main Outcomes and Measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P =.10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P =.19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P =.006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P =.01). This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections. ClinicalTrials.gov Identifier: NCT02142751.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

  • Gómez-Junyent, Joan
  • Lora-Tamayo, Jaime
  • Baraia-Etxaburu, Josu
  • Sánchez-Somolinos, Mar
  • Iribarren, Jose Antonio
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Staphylococcus aureus; Implant removal; Prosthetic joint infection, Staphylococcus aureus; Extracción de implantes; Infección de la articulación protésica, Staphylococcus aureus; Eliminació d’implants; Infecció de l'articulació protèsica, Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting., This study was supported by Plan Nacional I+D+I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), co-financed by the European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2004–2020. J. G-J was supported by a grant from the Spanish Ministry of Education (FPU 14/03124).